EGFR and breast carcinoma: Furthermore, when combined with erlotinib, an epidermal growth factor receptor (EGFR) inhibitor, EPZ015666 exhibits additive anticancer effects on MDA-MB-468, BT20, and HCC70 breast cancer cell lines, enhancing the efficacy of either treatment compared to when they were used alone (Fig. 5F) (127, 128).